Medicare Update: Beneficiaries Just Got New Lab Payment Rates
CMS’s preliminary 2027 lab fee schedule triggers steep Medicare cuts and rattles major diagnostics stocks.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The data, highlighted by GenomeWeb, indicate steep cuts to Medicare reimbursement for lab tests under the Protecting Access to Medicare Act (PAMA). Newsweek framed the change as a direct update to beneficiaries, noting that Medicare recipients have just received new lab payment rates. Coverage from a range of financial and industry outlets emphasizes the market impact of the CMS announcement.
Seeking Alpha described the resulting sell‑off in Labcorp shares as an “excellent opportunity,” while AD HOC NEWS recorded a 4.29 percent pre‑market decline for Quest Diagnostics. Both The Globe and Mail and The Motley Fool published pieces explaining why Labcorp Holdings and Quest Diagnostics stocks dropped on the same day. The consistent focus across these sources is the immediate negative reaction in equity prices for the two largest U.S. commercial laboratories, driven by investor anticipation of reduced revenue streams from the announced cuts.
Future developments to monitor include the finalization of the 2027 laboratory fee schedule, which CMS is expected to publish after a comment period. Investors will likely track any revisions that could moderate the steepness of the cuts, while laboratory companies may adjust guidance or strategic plans in response. Additionally, further commentary from industry analysts and potential regulatory feedback could influence subsequent stock movements for Labcorp, Quest Diagnostics, and other diagnostics firms.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (64% supported) Updated 51d ago.
Quick answers
What are the new Medicare lab payment rates for 2027?
CMS issued preliminary 2027 clinical laboratory fee schedule rates that indicate steep cuts to Medicare reimbursement for lab tests, as reported by the American Hospital Association, MedTech Dive, and GenomeWeb.
Why did Labcorp and Quest Diagnostics stocks fall?
Both companies saw share price declines on September 22, 2026, after the CMS announcement of reduced lab reimbursement rates, a reaction documented by AD HOC NEWS, The Globe and Mail, and The Motley Fool.
What role does PAMA play in the new rates?
The Protecting Access to Medicare Act (PAMA) governs how CMS calculates Medicare lab reimbursements, and the preliminary cuts for 2027 are being made under its framework, according to GenomeWeb.
Coverage (9)
- Labcorp: The CMS Selloff Represents An Excellent Opportunity Seeking Alpha · 54d ago
- Quest Diagnostics stock falls 4.29 percent ahead of the open AD HOC NEWS · 54d ago
- Why Labcorp Holdings Stock Dropped Today The Globe and Mail · 54d ago
- CMS Data Indicates Steep Cuts in Reimbursements for Lab Tests in 2027 Under PAMA GenomeWeb · 54d ago
- Why Labcorp Holdings Stock Dropped Today The Globe and Mail · 54d ago
- CMS issues preliminary 2027 clinical laboratory fee schedule rates American Hospital Association · 54d ago
- Why Quest Diagnostics Holdings Stock Dropped Today The Motley Fool · 54d ago
- CMS sets preliminary cuts to Medicare lab reimbursement rates MedTech Dive · 54d ago
- Medicare Update: Beneficiaries Just Got New Lab Payment Rates Newsweek · 54d ago
Topics
Related trends
'We feel blindsided': Minnesota seniors navigate unexpected Medicare cost increases
Medicare Advantage plan withdrawals and cost spikes are hitting seniors across multiple states ahead of 2027 enrollment changes.
Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets
Quest Diagnostics has paid $13 million to settle a federal lawsuit alleging it used New York Giants perks to secure patient referrals.
Your job-based insurance cut GLP-1 coverage. Here are some options
Insurers are cutting coverage for GLP-1 weight-loss drugs, with coverage dropping from 57% to 53% between 2025 and 2026, while list prices range from $500 to over $1,000 monthly.
Medicare Advantage vs. Traditional Medicare: What You Need to Know
Choosing between Medicare Advantage and Original Medicare involves critical trade-offs in costs, benefits, and provider networks.
CMS makes it official, codifying Medicare drug price negotiations established under IRA
CMS finalizes rule codifying Medicare drug price negotiations under the Inflation Reduction Act, advancing the program into its fourth negotiation cycle.
Remote-Patient Monitoring Companies Dodge Medicare Shift—For Now
Medicare delays a controversial remote patient monitoring restriction to 2029, offering a temporary reprieve for providers.